Our campaigns and advocacy team attended the European Haematology Association conference in June to hear the latest news from research, clinical trials and clinical practice. Here are the latest updates from the conference.
Highlights in ALL included:
- Genetic changes in ALL
Identifying the genetic changes that have happened in ALL cells is becoming increasingly important as new treatments are being developed. It allows therapies to be more targeted to the underlying changes that are driving the disease.
Immunotherapies use the patients own immune response to treat ALL. There are a number of emerging immunotherapies, currently in clinical trials and the research was presented at the meeting.
- CAR-T therapy
A very hot topic in the treatment of ALL at the moment. CAR-T therapy is the first gene therapy to be approved for use in America and it has now been approved in Europe. Much research was presented at the meeting, including clinical trial data and looking for new cancer cell markers that can be targeted with edited immune cells.
Learn more from the clinicians in the video below:
View more videos from the conference by visiting our YouTube page here.